CEM-102

DRUG2 trials

Sponsors

Arrevus Inc.

Conditions

Infected SpacersProsthetic Joint Infections of HipProsthetic Joint Infections of KneeSkin Diseases, Bacterial

Phase 2

Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections

CompletedNCT00948142

Arrevus Inc.Skin Diseases, Bacterial

Start: 2009-08-31End: 2010-03-31Updated: 2019-04-19

Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection

TerminatedNCT01756924

Arrevus Inc.Infected Spacers, Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee

Start: 2012-12-31End: 2014-07-31Updated: 2019-04-19

Related Papers

A Randomized Study Evaluating Oral Fusidic Acid (CEM-102) in Combination With Oral Rifampin Compared With Standard-of-Care Antibiotics for Treatment of Prosthetic Joint Infections: A Newly Identified Drug–Drug Interaction

UNC Libraries2020-04-16

A Randomized Study Evaluating Oral Fusidic Acid (CEM-102) in Combination With Oral Rifampin Compared With Standard-of-Care Antibiotics for Treatment of Prosthetic Joint Infections: A Newly Identified Drug–Drug Interaction

Clinical Infectious Diseases2016-09-2843 citations

A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections.

2011-06-0134 citations